Lustgarten Foundation funded researchers at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins have designed a multi-analyte blood test that can detect the presence of pancreatic cancer as part of a panel of eight common cancers (pancreas, ovary, liver, stomach, esophagus, colorectum, lung and breast) as reported in the online edition of Science today. The test utilizes combined assays for genetic alterations and protein biomarkers and has the capacity not only to identify the presence of relatively early cancer, but also to localize the organ of origin of these cancers.
“The potential this has for pancreatic cancer is unprecedented,” says Anne Marie Lennon, M.D., Ph.D., Associate Professor of Medicine, Director, Pancreatic Cyst Center of the Ludwig Center at the Johns Hopkins Kimmel Cancer Center. “We know that in 80-85 percent of pancreatic cancer cases, it’s detected too late, leaving the patient with few options. Developing a blood screening test for pancreatic cancer has been an urgent goal, because catching the disease early will be the way we get to long-term survival.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8213751-lustgarten-foundation-pancreatic-cancer-blood-test/
Exact Sciences Corp. (NASDAQ: EXAS) announced today that the U.S. Food and Drug Administration (FDA) has approved Cologuard, the company’s noninvasive, stool DNA colorectal cancer screening test. Cologuard is the first noninvasive screening test for colorectal cancer that analyzes both stool DNA and blood biomarkers and has been proven to find 92 percent of cancers and 69 percent of the most advanced precancerous polyps in average risk patients. Cologuard, which is available through healthcare providers, offers people 50 and older at average risk for colorectal cancer an easy–to–use screening test they can do in the privacy of their own home.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7092251-fda-approve-s-exact-sciences-cologuard-screening-test-colorectal-cancer/
Cancer is the leading cause of death by disease in children from ages 1 to 19 in the U.S. Yet, childhood cancer research and services are vastly and consistently underfunded. This weekend, Northwestern Mutual financial professionals and employees will support the fight against childhood cancer through its nonprofit partner, Alex’s Lemonade Stand Foundation (ALSF), by holding nearly 200 lemonade stands as part of the Foundation’s national fundraising initiative, Alex’s Lemonade Days (June 12-14).
Founded by Alex Scott (1996-2004) in 2004, Alex’s Lemonade Days is a three-day national event that grew out of Alex’s front yard lemonade stand. During Alex’s Lemonade Days, dedicated volunteers host thousands of Alex’s Lemonade Stands across the country, raising more than $1 million for childhood cancer research. June 2015 will mark the 12th Annual Lemonade Days, and will continue Alex’s mission to raise money one cup of lemonade at a time, renewing her idea that any contributor, at any age, can make a difference.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7422153-northwestern-mutual-lemonade-days/
To kick off Lung Cancer Awareness Month this November, the American Lung Association’s LUNG FORCE initiative, nationally presented by CVS Health, today announced its partnership with Grammy Award-winning singer Patti LaBelle to further educate the public about lung cancer, the leading cancer killer of women in the United States.
Personally affected by lung cancer, LaBelle hopes that lending her powerful voice to the cause will encourage all women to learn how they can make a difference in the fight to defeat lung cancer, which claims the life of one woman every eight minutes in the United States. Raising awareness is critical as only 1 percent of American women even have lung cancer on their health radar.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7664651-lung-force-patti-labelle-educate-public/
St. Jude Children’s Research Hospital®, uno de los principales centros de investigación y tratamiento del cáncer pediátrico se unió a Univision Radio, la mayor difusora de radio Hispana en los Estados Unidos, para realizar su evento radial anual Promesa y Esperanza®. Los radioyentes alrededor del país sintonizaron su estación favorita de Univision Radio el 7 y 8 de febrero y recaudaron más de $5.3 millones en efectivo y promesas monetarias. Los fondos recaudados ayudarán a cubrir los gastos de investigación y tratamiento del cáncer pediátrico y otras enfermedades terminales en los Estados Unidos, Puerto Rico y alrededor del mundo.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58260-st-jude-childrens-research-hospital-univision-radio-promesa-y-esperanza
“You have cancer.” Those three words are among the most dreaded and powerful a person can hear. In the case of Tony Harnell, the diagnosis of thyroid cancer was doubly frightening.
A vocalist/songwriter with a four-octave range, Harnell had toured in the U.S. with likes of Stryper, Twisted Sister and Great White and appeared on stages worldwide, entertaining legions of fans as lead singer with hard-rock band TNT.
To view Multimedia News Release, go to http://www.multivu.com/mnr/62578-american-college-endocrinology-tony-harnell-advocate-thyroid-cancer-aware
Personalised Medicine is the future of cancer treatment, but it presents major challenges for doctors and health services, the President of the European Society of Medical Oncology has said. Professor Rolf Stahel was speaking ahead of the 3rd Astellas Innovation Debate: i-Genes – What the DNA and Data Revolutions mean for our Health, taking place on Thursday 29th January 2015 at the Royal Institution of Great Britain.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7430351-professor-rolf-stahel-astellas-debate/
The Leukemia & Lymphoma Society (LLS), the world’s leading voluntary non-profit dedicated to blood cancers, released 30 “proof points” - one for each day of September, Blood Cancer Awareness Month - to demonstrate its impact on the cancer landscape and progress towards a world without blood cancers.
LLS has invested more than $1 billion in research to advance breakthrough therapies and cures for blood cancer patients. In many cases, those treatments are now helping patients with other cancers and chronic diseases. Due to its focus on blood cancers, survival rates are improving. Since the early 1960s, five-year survival rates for many blood cancer patients have doubled, tripled and even quadrupled.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554851-lls-blood-cancer-awareness-month/
Announced today by VICHY Laboratoires, the VICHY EXPOSOME GRANT will promote and encourage research activity on the skin exposome. One research grant of 15 000 € will be awarded annually to a research project proposal in the field of exposome and skin.
What is exposome?
The human body is subjected to and responds to complex exposures throughout the lifespan, including exposures from the environment, diet, lifestyle. For this highly complex interaction, the term exposome was recently coined by Dr. Christopher Wild at the World Health Organization‘s International Agency for Research on Cancer.
The exposome analysis, therefore, complements the human genome by providing a comprehensive description of individuals’ lifelong environmental exposures. Exposome research aims to look at the holistic view of the human body’s exposures, how the body responds to those exposures, and their combined effects.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7751451-vichy-announces-exposome-grant/
Evidence from the Childhood Cancer Survivor Study suggests that changes in childhood cancer treatment have reduced deaths from the late effects of cancer treatment and extended the lives of childhood cancer survivors. St. Jude Children’s Research Hospital investigators led the research, which will be presented today at the plenary session of the 2015 annual meeting of the American Society of Clinical Oncology (ASCO).
The study is one of four being featured at the plenary session press briefing, which highlights research that ASCO deems as having the highest scientific merit and greatest potential to affect patient care.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7532851-st-jude-cancer-research/
When a serious illness enters a family's life, there are many questions to ask and decisions to make. It is important to answer these questions quickly. The process can seem overwhelming. However, hospice care can be a wonderful resource for information about symptom management and comfort care. Hospice care professionals are available to help assess goals, pain management and care options during the decision-making process.
Are your symptoms minimal or moderate? Are these symptoms just starting to affect your life? If you want to continue treatment but also need comfort and symptom management, palliative care (often called comfort care) maybe an option. Palliative care is patient and family-centered care that optimizes quality of life by anticipating, preventing and treating suffering. Palliative care specialists address the physical, intellectual, emotional, social, and spiritual needs of patients and families, making sure they have access to all the information about the disease progression and the choices ahead. A patient can receive palliative care in conjunction with other treatments or therapies.
To view the multimedia release go to:
http://www.multivu.com/players/English/7429131-moments-of-life-by-hospice/
Going on the offensive against one of the most daunting challenges in cancer, The Leukemia & Lymphoma Society (LLS) today announced the launch of a groundbreaking, collaborative clinical trial for acute myeloid leukemia (AML), a deadly disease which has seen few improvements in treatments in more than 40 years.
Beat AML was announced yesterday by Vice President Biden, along with many new, Moonshot inspired initiatives across industry, non-profit and government.
AML is the most lethal of the blood cancers, which together are the third leading cause of cancer deaths in the U.S.; AML is responsible for more than 10,000 deaths each year. Despite advances in treating other blood cancers, the standard of treatment for AML – a combination of toxic chemotherapies – has remained the same for more than 40 years. Overall prognosis remains poor, with a five-year survival rate below 20 percent for patients over age 60.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554854-lls-beat-aml-acute-myeloid-leukemia/
